All In Biotech

Drug Trial Radar · NCT07489482

A Clinical Study Comparing the Relative Bioavailability and Safety of SHR-3167 Injection

A Randomized, Parallel, Open-label Clinical Study on the Bioavailability and Safety of Different Specifications of SHR-3167 Injection in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Apr 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Apr 2, 2026

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
Mar 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a randomized, parallel, open-label Phase I clinical trial aimed at comparing the bioavailability and safety of different specifications of SHR-3167 injection, with healthy subjects as the research subjects.

Conditions

  • Diabetes Mellitus

Interventions

  • SHR-3167 InjectionDrug

    SHR-3167 injection, different specifications.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The maximum plasma concentration (Cmax)Time frame: Day 1 - Day 71.
  2. The area under the blood drug concentration-time curve corresponding from time 0 to the last quantifiable concentration time (AUC0-t)Time frame: Day 1 - Day 71.
  3. The area under the blood drug concentration-time curve from time 0 to infinity (AUC0-∞)Time frame: Day 1 - Day 71.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xiangya Hospital, Central South University

    Changsha, Hunan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.